This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Tricida, Inc.
5/6/2021
Good day. Thank you for standing by and welcome to the Trifida First Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. Please be advised that today's call is being recorded. If you require any further assistance, Please press star zero. Thank you. I would now like to hand the conference over to your speaker today, Ms. Jackie Kussman. The floor is yours.
Thank you, Alex. Good afternoon, and thank you for joining the Tricita First Quarter 2021 Financial Results and Business Update Conference Call. In today's call, Garrett Klarner, our founder, CEO, and president, will discuss an update on our ongoing VALORCKD study, potential for near-term data based on first pre-specified interim analysis for early stopping for efficacy, and our strategy for re-engagement with the FDA. Jeff Parker, our COO and CFO, will then discuss our upcoming business activities and financial results for the first quarter and review our financial guidance. Please note that in today's call, we will be making various statements that include forward-looking statements as defined under applicable securities laws. Forward-looking statements include our anticipated activities, related to our ongoing renal outcomes trial, VALOR-CKD, our plans and interactions and communications with the FDA, our plans and expectations regarding potential pathways to approval of Averamer by the FDA, and our expectations regarding our financial runway. Management's assumptions, expectations, and opinions reflected in these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from any future results, performance, are achievements discussed in or implied by such forward-looking statements. Tricita can give no assurance that these statements will prove to be correct, and we do not intend and undertake no duty to update these statements. We also urge you to read the risks and uncertainties associated with our business that are described in our filings with the Securities and Exchange Commission. We issued our first quarter financial results press release this afternoon just after the close of markets. For copies of our press release, please go to www.tricita.com and follow the link to our investor relations page. At this time, I'd like to turn the call over to Gary.
Thank you, Jackie, and thank you all for joining us today. Our primary focus this year is on the continued execution of the valid CKD renal outcomes trial, which is designed to assess whether the variant can slow kidney disease progression in patients with metabolic acidosis and CKD. Given the complete response letter that we received last August and the appeal denied letter from the FDA's Office of New Drugs, which we discussed at length earlier this year, we believe the optimal path forward for the potential approval of Averma is to provide additional data to the FDA from the ongoing outcomes trial. We believe that positive data from valid CKD on Averma's ability to slow CKD progression or improve physical function would enable a productive discussion with the agency. I'll talk about our plans to re-engage with the FDA shortly, but first, let me provide an update on our trial progress. On slide three, as a reminder, LRCKD is a randomized, double-blind, placebo-controlled trial that is designed to enroll 600 subjects. The primary endpoint of the trial is the time to first occurrence of DD40, defined as renal death, ESRD, or a confirmed greater or equal 40% reduction in EGFR. The protocol includes two pre-specified interim analyses for early stopping for efficacy. Interim one will occur after 150 events, and interim two will occur after 250 events. If the criteria for early stopping are not met, the trial is scheduled to conclude when the Independent Unblinded Endpoint Adjudication Committee has positively adjudicated 511 DD40 events. The trial was designed with 87% power to show a 24% difference in primary endpoint events. Set another way, the assumed hazard ratio for the powering of the Valid CKD trial is 0.76. As you can see on slide four, as of May 4th, 2021, the Valid CKD trial has randomized 1,440 of 1,600 subjects with an average treatment duration of approximately 15 months. And the trial has accrued 95 subjects with positively adjudicated primary endpoint events towards our goal of 511 events. The projected event rate for valid CKD is laid out on slide five. So far, there are 95 subjects with adjudicated primary endpoint events. We've accrued 26 additional subjects with adjudicated events since our February 25th fourth quarter financial results call. Over the past two months, the rate of event accrual has increased and is currently tracking close to our mean estimate. The rate of accruing endpoint events is key to determining the timing of the interim analyses. Assuming that the accrual of endpoint events continues at the projected rate as previously communicated, we estimate that the number of adjudicated endpoint events necessary for the Interim 1 and Interim 2 analyses would occur in the second half of this year and sometime around mid-2022, respectively. On slide 6, at the bottom of the slide, you can see that our approach to the two interim analyses is to keep the majority of the alpha for the final analysis at 511 events and allocate meaningful alpha to the 250-event analysis. With very little alpha allocated to it, there's relatively low probability that the 150-event interim would lead to early stopping. Put another way, looking at the interim analyses, assuming the true hazard ratio is in line with our trial design, i.e. 0.76, we have a 1 percent chance of stopping at interim one and a 21 percent chance of stopping at interim two. the 65% power remaining for the final analysis at 511 events for an overall power of 87% for the trial. Given the hazard ratios observed in some of the academic trials related to metabolic acidosis in our own 301 trial, there's historic evidence that treated populations of metabolic acidosis patients may experience greater benefit than the retrospective predictive models would indicate. If we were to assume a true hazard ratio of .70 instead of .76, the probability of stopping early doubles to 40% at interim two. Extending the true hazard ratio to .6 and .5, the combined probability of stopping early at either the first or second interim analysis increases to 83% and 99% respectively. And if we were to observe a hazard ratio of .67 or less, at interim two, the trial would meet the criteria for early stopping for efficacy. As such, we consider interim two an important milestone for the valid CKD trial and alpha well spent. The interim analyses will be conducted by an independent unblinded interim analysis committee, and if this committee does not recommend stopping the trial early for efficacy, we will receive no information from the interim analyses. If, however, data from the trial were to yield a statistically significant result for the primary efficacy endpoint, it could potentially form the basis for resubmission of the NDA through the traditional approval pathway. Now turning to slide seven, we may find ourselves in a situation where we must stop the trial early for administrative reasons. As you're aware, conducting clinical trials is expensive and uncertainties can arise at any time. If we are unable to ensure that we have adequate resources to complete the trial in accordance with the protocol, or if other events occur which diminish our likelihood of reaching 511 events, we may explore the possibility of stopping the trial early for administrative reasons which could occur prior to or following either or both of the planned interim analyses. Any such decision would be made in the future based on a range of considerations. including our ability to reasonably stop and wind down the trial consistent with our regulatory and ethical obligations and within the confines of our financial runway. If we were to stop the study for administrative reasons, the data obtained from the study would be analyzed using all alpha remaining at that time. As an example of how the alpha would be applied to an administrative stop, I will use the 250 event time point as an illustration of the power of the trial at an administrative stop. Assuming a true hazard ratio of 0.76, if the trial were stopped for administrative reasons at 250 events, you would have 58 percent power to see 24 percent reduction in the VARAMER versus POSIWA endpoint events. To provide you with a sensitivity analysis, if the treatment effect in the VAR trial is slightly higher and we have a true hazard ratio of 0.70, the power increases to 81 percent if stopped at 250 events. switching from power to observed hazard ratio statistics, we could be successful at 250 events if the observed hazard ratio is 0.78. It is noteworthy that this hazard ratio is not much lower than the 0.83 hazard ratio required at the final analysis of 511 events shown on the prior slide. If the data from a trial after administrative software to yield statistically significant results for the primary efficacy endpoint, it could potentially form the basis for resubmission of the NDA through the traditional approval pathway. In the event that the primary endpoint is not met, we would evaluate other endpoints related to CKD progression as well as physical function and serum bicarbonate endpoint, which could inform our discussions with the FDA and or additional clinical investigation of the effect of Averma on these parameters. We've highlighted on slide eight the key CRL and ADL issues. We believe data from valid CKD will be very important in determining the regulatory path for approval of AVERMA. Ultimately, our goals are to, one, generate outcome data showing the impact of AVERMA on CKD progression, and two, show that the data are applicable to the U.S. population. If we are successful in both counts, we believe that the data could address the regulatory concerns expressed by the FDA and the CRL and ADL. I would note FDA's acceptance of the VAERS-CQD data in support of an NDA resubmission, including the acceptability of the data from non-U.S. countries or regions, which will comprise a substantial proportion of the data from the trial, will ultimately be a review issue. Further, the FDA may require additional clinical data beyond that provided by VAERS-CQD. For example, we know that about two-thirds of the subjects in the trial will be from Eastern Europe. So we anticipate that these subjects will account for two-thirds or more of the primary endpoint events. In the CRL, the FDA indicated that it believes differences in patient management, such as concomitant medications and diet, might affect the treatment response to Viverma and expressed a concern of the applicability of the 30131E trial data to a U.S. patient population. Our evaluation of the 30131E's serum bicarbonate data indicate that the etiology and treatment paradigms for CKD are substantially similar in the U.S. and Eastern Europe. and other baseline lab values are not substantially different. But we cannot be certain how the FDA will ultimately view the proportion of events from regions outside the U.S. in its evaluation of the outcomes data. We are preparing to analyze the value of CKD data once available to evaluate the effect of geographic region as a predictor of response to the VIRMA in the context of the multitude of other factors that play a role in asset-based buffering. Which brings me to our plans for future engagement with the FDA, as you can see on slide nine. We intend to re-engage with the FDA to discuss our options for traditional approval of VRMA. The timing of this interaction will ultimately be dependent on the availability of data and guidance we receive from our regulatory advisors. In the event that the trial is stopped early for efficacy at one of the interim analyses, we'll plan on a substantive discussion with the FDA with data in hand that will guide our plans for potential resubmission of the VRMA NDA. Based on the current estimated time for the interim analysis, our earliest estimate for resubmission of the NDA would be late 22 or early 23. Assuming the trial is stopped early for efficacy at one of the interim analyses, we believe this would be classified as a resubmission under the original NDA submission and as such would qualify for a six-month review. Clearly, the specifics related to any NDA resubmission and related timing will be determined for our future FDA interactions. Before I turn the call over to Jeff, I'd like to take a few moments on slide 10 to highlight our efforts to advance the understanding of metabolic acidosis and its serious complications. We sponsored or authored several presentations at the NKF Spring Clinical Meeting 2021 that occurred in early April. The topics covered and sponsored presentations by several key opinion leaders They included analyses of the association between metabolic acidosis and accelerated kidney decline, the association in kidney transplant recipients between metabolic acidosis and graft failure, and between metabolic acidosis and the higher risk of death. Tricita also presented in vitro data showing that VeroMed does not bind to or affect the iron-binding properties of other non-absorbed binder drugs that are prescribed to patients with CKD, such as Venvela, Veltasa, Loquelma, and K-Exfolate. More sponsored and in-house publications are planned for this year, and we'll continue to engage with the nephrology community to present our findings. With that, I'll turn the call over to Jeff.
You're reading a preview of the TCDA Q1 2021 earnings call.
Free account.